LYNE LABS

Executive Summary

LYNE LABS is a US-based contract development and manufacturing organization (CDMO) headquartered in Boston, Massachusetts. Founded in 2018, the company specializes in innovative drug delivery technologies and biologics manufacturing, with a focus on liquid dosage forms, unit-dose packaging, and powder technology. It positions itself as a strategic partner for pharmaceutical companies, offering end-to-end development and manufacturing services through win/win collaborations. LYNE LABS serves a niche but essential segment of the pharmaceutical supply chain, enabling clients to bring complex drug formulations to market efficiently. Despite its relatively recent founding, LYNE LABS leverages decades of industry expertise, as its roots trace back to 1965 with a revitalization in 1979. The company targets select client companies, emphasizing high-quality service and technological innovation. As a private entity, it operates with agility and a customer-centric approach, aiming to capture market share from larger CDMOs. With the growing demand for biologics and advanced drug delivery systems, LYNE LABS is well-positioned for steady growth, though its private nature limits public visibility. Key opportunities lie in expanding its client base and scaling manufacturing capabilities to meet rising industry needs.

Upcoming Catalysts (preview)

• Q4 2026New facility expansion for biologics manufacturing70% success
• Q3 2026Strategic partnership with a top-20 pharma company50% success
• Q2 2026Launch of novel unit-dose packaging platform80% success